Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of SON-1010 (IL12-FHAB) in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05408572
Recruitment Status : Not yet recruiting
First Posted : June 7, 2022
Last Update Posted : June 10, 2022
Sponsor:
Information provided by (Responsible Party):
Sonnet BioTherapeutics

Brief Summary:
SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy adults starting with sentinel participants at each dose level to carefully assess the safety, tolerability, PK, and PD of SON-1010.

Condition or disease Intervention/treatment Phase
Healthy Adult Biological: SON-1010 (IL12-FHAB) Early Phase 1

Detailed Description:
This is a study of SON-1010, a single-chain human Interleukin-12 (IL12) cytokine linked to a single-chain variable region (scFv) antibody fragment, known as the fully human albumin binding domain (FHAB). The albumin binding domain moiety of SON-1010 attaches to albumin in the bloodstream, resulting in significantly enhanced drug PK properties, potentially lower risk than IL12 alone, and a broader therapeutic index. Healthy volunteers will be assessed with single ascending doses of SON-1010. The design comprises up to 5 separate dosing cohorts, with a total of 8 participants (minimum of 7) in each cohort randomized to receive either SON-1010 (6 participants) or placebo (2 participants), for up to 40 participants.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Adaptive-Design, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Healthy Adults
Estimated Study Start Date : July 27, 2022
Estimated Primary Completion Date : December 30, 2022
Estimated Study Completion Date : December 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single Dose Level 1
6 healthy adults dosed with SON-1010 (Level 1) + 2 healthy adults dosed with Placebo
Biological: SON-1010 (IL12-FHAB)
SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Experimental: Single Dose Level 2
6 healthy adults dosed with SON-1010 (Level 2) + 2 healthy adults dosed with Placebo
Biological: SON-1010 (IL12-FHAB)
SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Experimental: Single Dose Level 3
6 healthy adults dosed with SON-1010 (Level 3) + 2 healthy adults dosed with Placebo
Biological: SON-1010 (IL12-FHAB)
SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Experimental: Single Dose Level 4
6 healthy adults dosed with SON-1010 (Level 4) + 2 healthy adults dosed with Placebo
Biological: SON-1010 (IL12-FHAB)
SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.

Experimental: Single Dose Level 5
6 healthy adults dosed with SON-1010 (Level 5) + 2 healthy adults dosed with Placebo
Biological: SON-1010 (IL12-FHAB)
SON-1010 is a single-chain human IL-12 cytokine linked to a single-chain variable region known as the FHAB.




Primary Outcome Measures :
  1. To evaluate the safety and tolerability of SON-1010 as a single-ascending dose (SAD) in healthy adults. [ Time Frame: Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29 ]
    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0


Secondary Outcome Measures :
  1. Serum and urine concentrations of SON-1010 will be determined at various time points [ Time Frame: Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29 ]
    Concentration vs time of SON-1010 will be measured using blood & urine samples taken at various time points on study

  2. Effect of SON-1010 on Serum cytokine levels [ Time Frame: Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29 ]
    Concentration of serum level of IL-2, IL-6, IL-10 will be measured using blood samples taken at various time points on study

  3. Evaluation of SON-1010 immunogenicity [ Time Frame: Study Duration - Week 1 on Day 1, 2, 3 ,4, 5. Follow-Up on Day 8, 10, 12, 15, 22, 29 ]
    Evaluate the immunogenicity of SON-1010 by measuring the number of patients developing anti-SON-1010 antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 54 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  • Participants must be medically healthy based on medical history, physical examination, and clinical laboratory testing.
  • Participants must be between 18 to 54 years of age, inclusive at the time of the informed consent.
  • May only be limited users of nicotine-containing products, including e-cigarettes, for at least 3 continuous months before the first dose of SON-1010, as confirmed by cotinine testing at screening and check-in (day -1). Social smoking is allowed up to 5 cigarettes per week as long as the participant is willing to abstain during confinement and the cotinine test is negative at check in. One repeat test is permitted at screening.
  • Must have negative drug/alcohol testing at screening and check-in (day -1). Screening drug/alcohol testing may be repeated once if deemed appropriate.
  • Must have vital signs (after sitting for at least 5 minutes) within the following ranges at screening and check-in (day -1):

    • Systolic blood pressure (BP), 90 to 140 mmHg, inclusive
    • Diastolic BP, 40 to 90 mmHg, inclusive
    • Heart rate (HR) >50 to ≤100 beats per minute
  • Must weigh >50 kg and ≤100 kg and have body mass index (BMI) ≥18 and ≤32 kg/m2 at screening.
  • Must have normal laboratory function by day -1 (note that the screening safety laboratory assessment may be repeated once to confirm the initial result and trending), defined as:

    • Creatinine level ≤ upper limit of normal (ULN) for age
    • Alanine aminotransferase (ALT) ≤ ULN
    • Total bilirubin ≤ ULN (unless participant has Grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome involving slow conjugation of bilirubin and direct bilirubin is <35%)
    • Albumin > lower limit of normal (LLN)
    • Coagulation International Normalized Ratio (INR) < 1.5
  • Females of childbearing potential, <1-year postmenopause who are not permanently sterile, must have a negative serum pregnancy test (beta-human chorionic gonadotropin [β-HCG]) at day -1, and agree to abstinence or use 2 highly effective methods of birth control for 30 days before the study, during the study, and for 30 days after the last dose of study intervention. Females who are not of childbearing potential (have had a hysterectomy, bilateral oophorectomy, or are ≥ 1-year postmenopause) do not need to use any contraception Nonchildbearing potential is defined as surgically sterile or postmenopausal (defined as 12 months of spontaneous amenorrhea). A follicle stimulating hormone (FSH) level >40 IU/L at screening will confirm postmenopausal status. If a participant is not sexually active, but becomes active, then she and her male partner must use 2 methods of adequate contraception.
  • Males and their female partners must use a highly effective method of birth control if female partner(s) is of childbearing potential and must not donate sperm during the study and for 90 days after the last dose of study intervention. Contraception guidance is described in the protocol.
  • Willing and able to provide signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Must be able to communicate well with Investigator and/or study site personnel and to comply with the requirements of the entire study.

Exclusion Criteria

  • Concurrent conditions that could interfere with safety and/or tolerability measurements.
  • Known history of allergy to any component of study intervention.
  • History of severe allergic/anaphylactic reaction.
  • Pregnancy and/or lactation
  • Receipt of any plasma-, protein-, or antibody-based therapeutic agents (e.g., growth hormones or monoclonal antibodies) within 3 months before the first dose of study intervention. Note: Influenza and COVID-19 vaccines will be allowed if administered more than 14 days before the first dose of study intervention.
  • Receipt of any investigational agent or treatment within 30 days or 5 half-lives, whichever is longer, before the first dose of study intervention.
  • Any active infection, including COVID-19, as determined by the currently applicable standard before study intervention.
  • Any acute noninfectious illness within 30 days before day 1.
  • Diagnosis of or positive screening result for active COVID-19, hepatitis B surface antigen (HbsAg), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus (HIV)-1 or HIV-2 antibody.
  • Unable or unwilling to cooperate with the Investigator for any reason.
  • History of any clinically relevant or chronic psychiatric, renal, hepatic, cardiovascular, pancreatic, neurologic, hematologic, or gastrointestinal disease (e.g., inflammatory bowel disease) or current clinically significant liver function test results. Mild anxiety and depression may be acceptable at the investigator's discretion.
  • Evidence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution, metabolism, or excretion of study intervention. History of cholecystectomy is acceptable.
  • Presence of clinically significant electrocardiogram (ECG) finding (confirmed upon repeat testing) that may interfere with any aspect of study conduct or interpretation of results, as follows:

    • QT interval corrected for HR according to Fridericia's formula (QTcF) > 450 in males or > 470 msec in females at screening or check-in (day -1).
    • Other ECG abnormalities clinically relevant in the judgment of the Investigator.
  • Use of any prescription or over-the-counter medications (apart from standard doses of analgesics), herbal products (e.g., St. John's Wort, garlic supplements, milk thistle), topical or inhaled steroids, or supplements/vitamins within 7 days before the first dose of SON-1010 and for the duration of the study, except for those approved by the Investigator and Sponsor (e.g., oral contraceptives, hormone replacement therapy).
  • Recent use of systemic steroids within 14 days of enrollment, except for physiologic doses for steroid replacement. Limited doses of systemic steroids (e.g., in patients with exacerbation of reactive airway disease) must have been completed at least 10 days before enrollment.
  • Use of biotin (i.e. Vitamin B7) or supplemental biotin higher than the daily adequate intake of 30 μg (FDA 2019). Patients who switch from a high dose to a dose of 30 μg/day or less are eligible.
  • History of alcohol or substance abuse within 6 months before the first dose of SON-1010 per the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
  • History of any major surgery within 3 months before the first dose of study intervention.
  • Donation or receipt of blood or blood product within 3 months before the first dose of SON-1010 and for the duration of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05408572


Contacts
Layout table for location contacts
Contact: Manuel DaFonseca 1-609-451-3912 clinical@sonnetbio.com

Locations
Layout table for location information
Australia, Victoria
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia, 3004
Contact: Chloe Hobbs         
Principal Investigator: Phillip Ryan, MD         
Sponsors and Collaborators
Sonnet BioTherapeutics
Investigators
Layout table for investigator information
Study Director: Richard Kenney, MD Sonnet BioTherapeutics
Layout table for additonal information
Responsible Party: Sonnet BioTherapeutics
ClinicalTrials.gov Identifier: NCT05408572    
Other Study ID Numbers: SB102
First Posted: June 7, 2022    Key Record Dates
Last Update Posted: June 10, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No